Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy.

Autor: Kitahara, Yoshihiro¹ (AUTHOR), Inoue, Yusuke¹ (AUTHOR) yinoue@hama-med.ac.jp, Yasui, Hideki¹ (AUTHOR), Karayama, Masato^1,2 (AUTHOR), Suzuki, Yuzo¹ (AUTHOR), Hozumi, Hironao¹ (AUTHOR), Furuhashi, Kazuki¹ (AUTHOR), Enomoto, Noriyuki¹ (AUTHOR), Fujisawa, Tomoyuki¹ (AUTHOR), Funai, Kazuhito³ (AUTHOR), Honda, Tetsuya⁴ (AUTHOR), Misawa, Kiyoshi⁵ (AUTHOR), Miyake, Hideaki⁶ (AUTHOR), Takeuchi, Hiroya⁷ (AUTHOR), Inui, Naoki^1,8 (AUTHOR), Suda, Takafumi¹ (AUTHOR)

Publikováno v: Respiratory Research. 1/10/2024, Vol. 25 Issue 1, p1-13. 13p.

Researchers from Hamamatsu University School of Medicine Discuss Research in Lung Diseases and Conditions (Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately...).

Publikováno v: Respiratory Therapeutics Week; 2/2/2024, p920-920, 1p